Loading...
CRISPR Therapeutics AG
CRSP•NASDAQ
Healthcare
Biotechnology
$64.76
$-1.30(-1.97%)
CRISPR Therapeutics AG (CRSP) Financial Performance & Income Statement Overview
Review CRISPR Therapeutics AG’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-90.57%
↓ 90.57%
Operating Income Growth
-109.66%
↓ 109.66%
Net Income Growth
-138.43%
↓ 138.43%
Operating Cash Flow Growth
45.17%
↑ 45.17%
Operating Margin
-1282.72%
↓ 1282.72%
Gross Margin
-239.71%
↓ 239.71%
Net Profit Margin
-1042.77%
↓ 1042.77%
ROE
-20.08%
↓ 20.08%
ROIC
-23.18%
↓ 23.18%
CRISPR Therapeutics AG (CRSP) Income Statement & Financial Overview
Review CRISPR Therapeutics AG's (CRSP) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $35.00M | $602000.00 | $517000.00 |
| Cost of Revenue | $57.51M | $4.15M | $11.15M | $56.98M |
| Gross Profit | -$57.51M | $30.85M | -$10.55M | -$56.46M |
| Gross Profit Ratio | $0.88 | -$17.53 | -$109.21 | |
| R&D Expenses | $72.48M | $77.31M | $82.16M | $75.32M |
| SG&A Expenses | $19.30M | $18.12M | $17.42M | $19.48M |
| Operating Expenses | $90.92M | $99.59M | $99.58M | $94.80M |
| Total Costs & Expenses | $148.42M | $99.59M | $110.73M | $151.78M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $4.74M | $4.84M | $4.80M | $4.84M |
| EBITDA | -$143.69M | -$59.75M | -$105.39M | -$146.41M |
| EBITDA Ratio | -$1.71 | -$175.07 | -$283.20 | |
| Operating Income | -$148.42M | -$64.59M | -$110.13M | -$151.26M |
| Operating Income Ratio | -$1.85 | -$182.94 | -$292.57 | |
| Other Income/Expenses (Net) | $13.54M | $27.98M | $25.06M | $26.14M |
| Income Before Tax | -$134.89M | -$36.61M | -$85.07M | -$125.12M |
| Income Before Tax Ratio | -$1.05 | -$141.31 | -$242.01 | |
| Income Tax Expense | $1.11M | $700000.00 | $876000.00 | $1.29M |
| Net Income | -$136.00M | -$37.31M | -$85.94M | -$126.41M |
| Net Income Ratio | -$1.07 | -$142.76 | -$244.50 | |
| EPS | -$1.58 | -$0.44 | -$1.01 | -$1.49 |
| Diluted EPS | -$1.58 | -$0.44 | -$1.01 | -$1.49 |
| Weighted Avg Shares Outstanding | $85.94M | $85.46M | $85.23M | $84.92M |
| Weighted Avg Shares Outstanding (Diluted) | $85.94M | $85.46M | $85.23M | $84.92M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan